You are here: Home » Archives for Management Changes

Curia Nomeia Steve como Vice-Presidente, Divisão Biológica

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) — A Curia, uma organização líder em pesquisa, desenvolvimento e fabricação por contrato, anunciou hoje a nomeação de Steve Lavezoli como vice–presidente da divisão biológica a vigorar a partir de 26 de fevereiro. Lavezoli liderará a divisão de produtos biológicos da Curia, supervisionando seus serviços de descoberta, desenvolvimento e fabricação.

“Este é um momento emocionante para a nossa equipe de produtos biológicos, e temos muito prazer em ter Steve a bordo”, disse o CEO da Curia, Philip Macnabb. “A vasta experiência de Steve com liderança de operações comerciais para desenvolvimento e fabricação de produtos biológicos o torna perfeito para liderar nossos esforços de produtos biológicos. Sob sua orientação, estou certo de que promoveremos nossa missão de mudar a vida das ciências da vida.”

Lavezoli trabalhou recentemente na Scorpius Biologics, uma startup de CDMO focada no desenvolvimento e fabricação de produtos biológicos microbianos e de mamíferos como vice–presidente de operações comerciais. Antes de ingressar na Scorpius, ele passou quatro anos na Catalent Biologics, focado no desenvolvimento de negócios de medicamentos nos EUA para programas clínicos em estágio inicial e, posteriormente, focado na integração de programas comerciais em estágio avançado. Ele também passou 12 anos na indústria de gases industriais na Linde Gas antes de ingressar na W.L. Gore na nova divisão biofarmacêutica para ocupar a função de desenvolvimento comercial/de mercado em itens de uso único de medicamentos a granel. Ele fez bacharelado em engenharia química na Pennsylvania State University.

“A Curia ocupa uma posição única na indústria de CDMO com uma impressionante oferta integral”, disse Lavezoli. “É uma honra fazer parte de uma equipe com um conhecimento científico tão profundo e um propósito orientado por valores para gerar um impacto positivo na vida dos pacientes.”

Saiba mais sobre as ofertas de produtos biológicos da Curia aqui: https://curiaglobal.com/biologics/

Sobre a Curia
A Curia é uma Organização de Desenvolvimento e Fabricação por Contratos (CDMO) com mais de 30 anos de experiência, uma rede integrada de 27 locais em todo o mundo e mais de 3.500 funcionários em parcerias com clientes biofarmacêuticos para lançar no mercado terapias que mudam a vida. Nossas ofertas de produtos biológicos e moléculas pequenas abrangem a descoberta através da comercialização, com capacidades regulatórias e analíticas integradas. Nossos especialistas científicos e de processos, e instalações de última geração oferecem a melhor experiência em fabricação de medicamentos e produtos farmacêuticos. Da curiosidade à cura, proporcionamos todas as etapas para a melhoria da vida dos pacientes. Visite–nos em curiaglobal.com.

Contato Corporativo:
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Foto deste comunicado disponível em: https://www.globenewswire.com/NewsRoom/AttachmentNg/f9784607–495c–40d3–9e39–b65c8147d1c5


GLOBENEWSWIRE (Distribution ID 9042529)

Curia ernennt Steve Lavezoli zum Vice President, Biologika

ALBANY, New York, Feb. 23, 2024 (GLOBE NEWSWIRE) — Curia, ein führendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen, hat heute bekanntgegeben, dass Steve Lavezoli mit Wirkung vom 26. Februar zum Vice President, Biologika, ernannt wurde. Herr Lavezoli wird die Biologika–Abteilung von Curia leiten und die Bereiche Entdeckung, Entwicklung und Herstellung beaufsichtigen.

„Dies ist eine aufregende Zeit für unser Biologika–Team, und wir freuen uns, Herrn Lavezoli an Bord zu haben“, so Philip Macnabb, CEO von Curia. „Die bemerkenswerte Erfahrung von Herrn Lavezoli in der Leitung kommerzieller Operationen für die Entwicklung und Herstellung von Biologika macht ihn zu einer natürlichen Wahl für die Leitung unserer Biologika–Aktivitäten. Ich bin zuversichtlich, dass wir unter seiner Führung unseren Auftrag, die Biowissenschaften zu verändern, weiter vorantreiben werden.“

Herr Lavezoli war zuletzt als Vice President of Commercial Operations bei Scorpius Biologics tätig, einem Startup–CDMO, das sich auf die Entwicklung und Herstellung von mikrobiellen und Säugetier–Biologika konzentriert. Bevor er zu Scorpius kam, verbrachte er vier Jahre bei Catalent Biologics, wo er sich auf die Geschäftsentwicklung von Arzneimittelsubstanzen in den USA für klinische Programme in der Frühphase und später auf die Integration kommerzieller Programme in der Spätphase konzentrierte. Darüber hinaus war er 12 Jahre in der Industriegasebranche bei Linde Gas tätig, bevor er zu W.L. Gore in die Startup–Biopharmazie–Abteilung wechselte, wo er an einer kommerziellen Geschäfts–/Marktentwicklungsfunktion für Einwegartikel mit Bulk–Arzneimitteln arbeitete. Er erwarb seinen B.S. in Chemietechnik an der Pennsylvania State University.

„Curia hat eine einzigartige Position in der CDMO–Branche mit einem beeindruckenden ganzheitlichen Angebot“, so Lavezoli. „Es ist eine Ehre, in einem Team mit so großer wissenschaftlicher Expertise und einem werteorientierten Ziel zu arbeiten, um das Leben von Patienten positiv zu beeinflussen.“

Erfahren Sie hier mehr über das Biologika–Angebot von Curia: https://curiaglobal.com/biologics/

Über Curia
Curia ist ein Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen (CDMO) mit mehr als 30 Jahren Erfahrung, einem integrierten Netzwerk aus 27 globalen Standorten und über 3.500 Mitarbeitern, das mit Kunden aus dem Bereich der Biopharmazie zusammenarbeitet, um lebensverändernde Therapien auf den Markt zu bringen. Unser Angebot an Biologika und kleinen Molekülen reicht von der Entdeckung bis zur Vermarktung und umfasst integrierte regulatorische und analytische Kompetenzen. Unsere wissenschaftlichen und verfahrenstechnischen Experten sowie unsere hochmodernen Anlagen bieten erstklassige Erfahrung in der Herstellung von Wirkstoffen und Arzneimitteln. Von der Neugierde bis zur Heilung leisten wir jeden Schritt, um das Leben der Patienten zu verbessern. Besuchen Sie uns unter curiaglobal.com.

Kontakt zum Unternehmen:
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Ein Foto zu dieser Mitteilung ist verfügbar unter: https://www.globenewswire.com/NewsRoom/AttachmentNg/f9784607–495c–40d3–9e39–b65c8147d1c5


GLOBENEWSWIRE (Distribution ID 9042529)

Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26. Lavezoli will lead Curia’s biologics division, overseeing its discovery, development and manufacturing services.

“This is an exciting time for our biologics team, and we are pleased to have Steve on board,” said Curia CEO Philip Macnabb. “Steve’s remarkable breadth of experience leading commercial operations for biologics development and manufacturing makes him a natural fit to lead our biologics efforts. Under his guidance, I have every confidence that we will further our mission of life–changing life science.”

Lavezoli most recently worked for Scorpius Biologics, a startup CDMO focused on microbial and mammalian biologics development and manufacturing as the vice president of commercial operations. Prior to joining Scorpius, he spent four years with Catalent Biologics, focused on drug substance business development in the U.S. for early–stage clinical programs and later focusing on late–stage commercial program integration. He also spent 12 years in the industrial gasses industry with Linde Gas before joining W.L. Gore in the startup biopharmaceutical division to work on a commercial business/market development role for bulk drug substance single–use items. He earned his B.S. in chemical engineering from Pennsylvania State University.

“Curia holds a unique position in the CDMO industry with an impressive end–to–end offering,” said Lavezoli. “It’s an honor to join a team with such deep scientific expertise and values–driven purpose to drive a positive impact on patients’ lives.”

Learn more about Curia’s biologics offerings here: https://curiaglobal.com/biologics/

About Curia
Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with biopharmaceutical customers to bring life–changing therapies to market. Our biologics and small molecule offerings span discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state–of–the–art facilities deliver best–in–class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to improve patients’ lives. Visit us at curiaglobal.com.

Corporate Contact:
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/f9784607–495c–40d3–9e39–b65c8147d1c5


GLOBENEWSWIRE (Distribution ID 9041965)

Halo Investing Appoints Hashbeer Ali as Executive Vice President – Institutional Sales, Middle East & Africa

CHICAGO, Oct. 05, 2023 (GLOBE NEWSWIRE) — Halo Investing ("Halo"), an award–winning platform for Protective Investments, is delighted to announce the appointment of Hashbeer Ali as Executive Vice President "" Institutional Sales for the Middle East & Africa at Halo Investing MEA Ltd., a regulated entity by ADGM's Financial Services Regulatory Authority. With a career spanning more than two decades in banking and derivatives sales, Hashbeer brings a wealth of experience and expertise to the Halo team.

Mr. Ali's extensive career in the financial industry has been marked by a commitment to excellence and a deep understanding of derivatives markets. His background includes notable engagements with local banks, where he played a pivotal role in shaping and executing derivative strategies. His proven track record of delivering exceptional results and building strong client relationships aligns seamlessly with Halo Investing's mission to grow access to innovative investment solutions.

"We are thrilled to welcome Hashbeer Ali to the Halo family," said Sadiq Hussain, Senior Executive Officer. "His impressive background and industry knowledge will be instrumental in advancing our institutional sales efforts and driving our mission to revolutionize the way structured investment products are accessed and managed."

Hashbeer Ali's appointment reinforces Halo Investing's commitment to building a team of industry leaders dedicated to delivering cutting–edge investment solutions to clients throughout the Middle East and Africa. His role as Executive Vice President "" Institutional Sales will encompass developing and executing strategic sales initiatives while strengthening Halo's presence in the institutional marketplace.

"I am excited to join Halo Investing, a company that is at the forefront of innovation in the structured investment space," Hashbeer Ali commented. "I look forward to leveraging my experience to contribute to Halo's continued growth and success."

Hashbeer Ali's addition to the Halo team is a significant milestone, marking the company's ongoing expansion and dedication to providing institutional clients with access to innovative and tailored investment solutions.

For media inquiries, please contact:

Halo Investing
Vladislav Moldavskiy
vlad.moldavskiy@haloinvesting.com

About Halo Investing

Halo Investing MEA Ltd. ("Halo MEA") is licensed and regulated by Abu Dhabi Global Market ("ADGM")'s Financial Services Regulatory Authority ("FSRA"). Halo MEA is a wholly owned subsidiary of Halo Investing, Inc. and authorized to provide financial services to professional clients and market counterparties only. Halo MEA acts solely as a distributor/selling agent and is not the issuer or guarantor of any structured product. For more information, please visit: http://www.haloinvesting.ae.

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/8c4652d5–bdee–478f–aa1a–ba37dd83f351


GLOBENEWSWIRE (Distribution ID 8944629)

William Ruto, President of Kenya, joins GCA Advisory Board

Nairobi, Kenya, Sept. 29, 2023 (GLOBE NEWSWIRE) — William Ruto, President of the Republic of Kenya and Chair of the Committee of African Heads of State and Government on Climate Change has accepted an invitation from Ban Ki–moon, 8th Secretary–General of the United Nations and Chair of the Global Center on Adaptation (GCA) and CEO Professor Patrick Verkooijen, to join the GCA Advisory Board.

During a high–level official meeting which took place today at the State House in Nairobi , Professor Patrick Verkooijen and President Ruto discussed a roadmap to guide the mobilisation of the financial commitments for adaptation which were made at the Africa Climate Summit hosted by the President in Nairobi earlier this month.

The Africa Adaptation Acceleration Program (AAAP) Country Compacts, announced during the Leaders' Dialogue on Adaptation, will drive the doubling down and scaling of adaptation action across the world's most climate–vulnerable continent. The country–led investment roadmaps, initiated by the Government of Kenya, outline adaptation investment priorities, financing needs, and finance mobilization strategies for implementing climate adaptation measures connected to the priorities outlined in National Adaptation Plans and other national strategies.

Recent research from GCA showed Africa may need a nearly tenfold increase in climate adaptation funding to $100 billion a year if it is to buttress its infrastructure, improve climate early warning systems and shield its agriculture from climate change.

On accepting the invitation, William Ruto, President of the Republic of Kenya said:
"African governments, businesses and communities have paid heavily for climate–related destruction and disruption, and have already invested heavily in adaptation action, but we need stronger international partnerships to support adaptation more than ever before. The Africa Adaptation Acceleration Program , the world's largest adaptation program resulting from collaboration between GCA, the University of Nairobi, African Development Bank and the African Union Commission, is the best vehicle we have to mobilize additional funding. I look forward to working closely with Professor Verkooijen and the Board to build on the US$6.7 billion that the AAAP has already invested in resilient climate projects in 27 countries since 2021. By working together I am confident that we will make great progress in ensuring that international commitments to deliver highly strategic and comprehensive adaptation responses are fulfilled."

Professor Patrick Verkooijen, CEO of GCA and Distinguished Chair of the Wangari Maathai Institute said:
"It is only by adapting to climate change that Africa can reach its potential. Yet promised climate finance""which is necessary to underpin wider development goals""remains critically short of what is needed. President Ruto has played a crucial role in the implementation of the Africa Adaptation Acceleration Program across the continent and I commend his leadership in hosting the Africa Climate Summit. I look forward to our continued collaboration to ensure the Summit outcomes are delivered for Africa's march to sustainable economic transformation and green growth."

During the Africa Climate Summit, President Ruto announced Kenya will host regional headquarters for GCA in Nairobi:
"I have had opportunity to interact with the Global Center for Adaptation, an international organisation based in Rotterdam in the Netherlands, whose constitution is an appealing emblem of our aspirations, from the aspirational design of its global headquarters and futuristic regional headquarters in Nairobi, comprising green walls and roof as well as rain gardens, to the collaborative culture of its staff. Unsurprisingly, the Center is intended to inspire the world to thrive with nature instead of pursuing the dangerous course of seeking to thrive at nature's expense."

It is expected the new Africa headquarters will open in Nairobi in January 2025.

Notes to Editors

About the Global Center on Adaptation
The Global Center on Adaptation (GCA) is an international organization that works as a solutions broker to accelerate action and support for adaptation solutions, from the international to the local, in partnership with the public and private sectors. Founded in 2018, GCA operates from the largest floating office in the world, located in Rotterdam, the Netherlands. GCA has a worldwide network of regional offices in Abidjan, Cote d'Ivoire; Dhaka, Bangladesh, and Beijing, China.

About the Africa Adaptation Acceleration Program
The Africa Adaptation Acceleration Program (AAAP) is a joint initiative of the African Development Bank and the Global Center on Adaptation (GCA). It aims to mobilize $25 billion, over five years, to accelerate and scale climate adaptation action across the continent. This ambition is delivered through the AAAP Upstream Financing Facility managed by the Global Center on Adaptation and the African Development Bank's climate action window in the ADF replenishment. AAAP works across four pillars to achieve transformational results: Climate–Smart Digital Technologies for Agriculture and Food Security; African Infrastructure Resilience Accelerator; Youth Empowerment for Entrepreneurship and Job Creation in Climate Adaptation and Resilience and Innovative Financial Initiatives for Africa.

Attachment


GLOBENEWSWIRE (Distribution ID 8930853)

Impulse Dynamics Announces Leadership Changes

MARLTON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, announced new leadership appointments, including Jason Spees to Chief Executive Officer, Shlomi Nachman to Chairman of the Board, and John Liddicoat, M.D., as a member of the Board of Directors. Spees was recently President and Chief Commercial Officer at Impulse Dynamics and brings a depth of medical device industry experience from commercial leadership roles. Nachman most recently was the Company Group Chairman at Johnson & Johnson, overseeing the Cardiovascular and Specialty Solutions & Vision Group. Liddicoat most recently served as Executive Vice President and President of the Americas Region and Enterprise Technology & Innovation function at Medtronic.

"I am pleased to lead the Impulse Dynamics team, focusing on a strong commercialization strategy and our commitment to an ongoing pace of innovation to change the course of treatment for patients living with heart failure," said Spees. "We find ourselves in a unique position to capitalize on robust clinical data and a lineup of cutting–edge technologies, exemplified by the Integra–D trial featuring the groundbreaking single device that integrates our CCM technology with implantable cardioverter defibrillator (ICD) technology. I look forward to working closely with the board and the leadership team to optimize the company for its next phase of commercial acceleration."

"I am honored to join the board of an organization that has showcased substantial contributions to the advancement of heart failure treatment," said Shlomi Nachman. "Over 64 million people suffer from heart failure, and many of those treated are not experiencing the higher quality of life they deserve. With CCM therapy and its future product pipeline, we are in the exciting position of being able to help millions of these patients to feel better and lead fuller lives," Nachman added. "I'm looking forward to working with the leadership team and the board to ensure a direct path to ongoing innovation and commercial success."

"I've been watching Impulse Dynamics and its technology from the sidelines for many years, and I am excited to now be able to join the team," said Liddicoat. "I look forward to working with a strong leadership team to lead innovation–driven growth as we aim to enhance the standard of care for heart failure patients across the globe."

Jason Spees joined the company as President and Chief Commercial Officer in July 2021. He brings more than two decades of successful leadership roles in the medical device industry. Spees was most recently Senior Vice President of Sales and Marketing for Biotronik in the areas of cardiac rhythm management, cardiovascular intervention, peripheral vascular intervention, diagnostics, and digital health. Prior to Biotronik, Spees was the Chief Commercial Officer of Preventice Solutions, along with multiple leadership positions, including Vice President of Sales for Boston Scientific. He holds a B.S. in Operations Research and Engineering from the United States Air Force Academy and an M.A. in Public Management – Finance from the University of Maryland.

Shlomi Nachman was the Company Group Chairman of Cardiovascular and Specialty Solutions and Visions Group within Johnson & Johnson's Medical Devices sector. Nachman was a member of the Medical Devices Group Operating Committee, where he led a diverse portfolio of six medical device businesses, including Electrophysiology, Neurovascular Intervention, Ear, Nose & Throat, Breast Aesthetics, Optometry and Ophthalmology. Before that, Nachman had various roles with increased scope and responsibilities, including Worldwide President of Biosense Webster and Cordis. His career at Johnson & Johnson spanned over 27 years, comprising multiple leadership positions with a proven track record of success that has recognized the ability to drive growth, innovation, and architect business turnarounds. Additionally, Nachman has accrued deep knowledge in all aspects of medical devices, such as general management, strategy, L&A, finance, product development, operations, sales and marketing, and research and development. Nachman was born in Israel and holds a B.S. in Management and Economics from the Technion Institute, as well as a diploma in electrical engineering from the Amal Technical School.

John Liddicoat brings a history of transformational leadership focused on execution. He spent 16 years at Medtronic, driving the strategic direction and global operations of increasing size and scope, including the Structural Heart, Cardiac Rhythm, and Heart Failure businesses. In his most recent role as Executive Vice President and President of the Americas region and the Enterprise Innovation and Technology function, he was responsible for designing and implementing go–to–market strategies to deliver above–market growth across North and South America. Liddicoat graduated medical school from the University of Chicago, completed a residency in general and cardiothoracic surgery at Johns Hopkins Hospital, and served on the faculty of Harvard Medical School. An innovator and entrepreneur, he has also served as a consultant to venture capital firms and early–stage medical device companies.

About the Optimizer Integra CCM–D System and CCM Therapy

The Optimizer Integra CCM–D System is an investigational device that combines CCM therapy and ICD therapy into one device. This device is being used in an FDA–approved Investigational Device Exemption (IDE) study and is not available for sale in the United States.

Impulse Dynamics currently offers the Optimizer system that is FDA–approved and CE–marked. The Optimizer system delivers CCM therapy "" the company's proprietary technology "" to the heart. CCM therapy has been designed by Impulse Dynamics to improve the heart's contraction, allowing more oxygen–rich blood to be pushed out through the body. CCM therapy is indicated to improve the 6–minute hall walk, quality of life, and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline–directed medical therapy, are not indicated for CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent.

CCM therapy delivers non–excitatory electrical pulses from the implantable Optimizer device in a manner designed to improve heart contraction. CCM therapy sends unique electrical pulses to the heart cells during their absolute refractory period. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, and CCM therapy has been published in more than 120 peer–reviewed journal articles.

About Impulse Dynamics

Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in heart failure patients. CCM therapy is delivered through the Optimizer system, which includes an IPG implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 9,000 patients have received the therapy as part of clinical trials and real–world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com or follow the company on LinkedIn, Twitter, and Facebook.

Forward–Looking Statements

This press release contains forward–looking statements. All statements other than statements of historical facts contained in this press release are forward–looking statements. In some cases, you can identify forward–looking statements by terms such as ""may,'' ""will,'' ""should,'' ""expect,'' ""plan,'' ""anticipate,'' ""could,'' ""intend,'' ""target,'' ""project,'' ""contemplate,'' ""believe,'' ""estimate,'' ""predict,'' ""potential'' or ""continue'' or the negative of these terms or other similar expressions, although not all forward–looking statements contain these words. Forward–looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and CCM therapy combined with an ICD delivered via a single device (CCM–D), and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short–term and long–term benefits of the Optimizer Integra CCM–D System and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward–looking statements are based on management's current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward–looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company's future research and development costs, capital requirements and the company's needs for additional financing; commercial success and market acceptance of CCM therapy; the company's ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company's ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company's business model and strategic plans for its products, technologies and business, including its implementation thereof; the company's ability to expand, manage and maintain its direct sales and marketing organization; the company's ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company's ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward–looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward–looking statements contained herein. These forward–looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release.

###


GLOBENEWSWIRE (Distribution ID 8924737)

Gemcorp Capital appoints former UK Middle East Trade Commissioner to lead regional expansion

DUBAI, United Arab Emirates, Sept. 03, 2023 (GLOBE NEWSWIRE) — Gemcorp Capital Management today announces its expansion in the Middle East. The new regional operation will be led by Simon Penney, formally His Majesty's Trade Commissioner for the Middle East for the UK Government. This strategic move reflects Gemcorp's continued commitment to building a local presence in the emerging markets and focus on the Middle East region's ambitious growth plans and investment opportunities.

Simon Penney's extensive experience and leadership will be instrumental in driving Gemcorp's origination and fundraising activities in the region and developing partnerships with Gulf investors and institutions to access projects across the emerging markets. Under his tenure as the UK's trade commissioner, trade with the region hit all–time highs alongside establishing multi–billion dollar investment partnerships with a number of Gulf countries. Simon has spent most of his career in the banking sector leading financial institutions across Europe, the Middle East, Africa and Asia. These included roles as: Head of Wholesale and International Banking at First Gulf Bank (UAE); CEO, Middle East and Africa at Royal Bank of Scotland; and CEO at ABN AMRO Bank (South Africa).

Gemcorp Capital's Chief Executive Officer, Atanas Bostandjiev, said: “The region's strategic location, robust infrastructure and business–friendly environment serve as an ideal gateway to access the exciting opportunities that the Middle East and surrounding regions have to offer. Developing a true partnership with local institutions is one of our key business principles. We look forward to applying our emerging markets expertise to investing in the region and aspire to become an important conduit between the Middle East and Africa and the wider emerging markets. With Simon at the helm of our regional business, we aim to become a regional partner of choice for infrastructure, technology and energy transition opportunities.”

Simon Penney expressed enthusiasm about the new role and the opportunities it presents: “I am excited to be leading Gemcorp Capital's operations in the Middle East. The region's crucial geographical and geopolitical position make it an ideal launchpad for Gemcorp Capital's continued growth.

“Gemcorp Capital has consistently demonstrated expertise in navigating the complexities of emerging markets, fostering capital investment and job creation and generating sustainable returns for its investors."

About Gemcorp Capital Management

Gemcorp Capital is as an independent investment management firm focused on emerging markets. Gemcorp Capital has facilitated over US$7 billion worth of investments in credit and equity transactions since inception. The firm is looking to invest at least $10 billion in Africa over the next decade, mainly in the form of debt deals in partnership with other institutional investors.

Media Enquiries:

gemcorp@citigatedewerogerson.com


GLOBENEWSWIRE (Distribution ID 8915072)

WATKINS WELLNESS EXPANDS INTO SAUNA CATEGORY THROUGH THE ACQUISITION OF SAUNA360

Vista, California, July 31, 2023 (GLOBE NEWSWIRE) — Watkins Wellness, a leader in hot tubs and aquatic fitness systems, today announced the expansion of its portfolio of personal well–being products and entry into the sauna category as a result of the pending acquisition of Sauna360 Group Oy ("Sauna360") by Watkins Wellness' parent company, Masco Corporation. Sauna360 is a leading global manufacturer of sauna solutions, and its portfolio of products includes traditional, infrared, and wood–burning saunas as well as steam showers, rooms and generators. These products are sold primarily in the United States, Europe and throughout the rest of the world under the Tyl, Helo, Kastor, Finnleo, and Amerec brands. The transaction is expected to close in the third quarter, subject to regulatory approval.

"We are thrilled to welcome Sauna360 to our organization and to expand our portfolio of industry–leading products aimed at promoting wellness and helping our customers feel good and live well!" said Vijaikrishna (VJ) Teenarsipur, President of Watkins Wellness. "Sauna360 brings a wealth of industry knowledge and expertise to our business. We look forward to leveraging the synergies between our businesses, which will allow us to better serve our dealer partners, consumers and, ultimately, the growing wellness market."

"I am very pleased for Sauna360 to become part of Watkins Wellness. Sauna360's business has grown in recent years, and becoming part of Watkins Wellness will further strengthen our capability and ambition to be a leading sauna player. The dealer distribution strategy, common focus on wellness and similar company cultures make this a true strategic fit," said Pekka Lettijeff, President & CEO of Sauna360 Group.

Founded in 2008 as a merger between two leading sauna companies, Helo and Tyl, Sauna360 brings decades of industry knowledge and experience resulting from a strong history, with Helo's origin dating back to 1919 and Tyl's to 1949. The company is headquartered in Finland and has approximately 180 employees located in Finland, Sweden, the United States, and England.

About Watkins Wellness

Watkins Wellness, established in 1977 in Vista, California, is dedicated to promoting wellness to consumers to help them feel good and live well. The company's growing portfolio of well–being products for at–home use provides multiple pathways to wellness. Our portfolio of brands includes Hot Spring Spas, Caldera Spas, Freeflow Spas, Fantasy Spas, and Endless Pools Fitness Systems, sold predominantly through a specialty dealer network of more than 1,000 dealer partners located in 70+ countries. Watkins Wellness is a wholly owned subsidiary of Masco Corporation (NYSE: MAS).

About Masco Corporation

Headquartered in Livonia, Michigan, Masco Corporation is a global leader in the design, manufacture and distribution of branded home improvement and building products. Our portfolio of industry–leading brands includes BEHR paint; Delta and Hansgrohe faucets, bath and shower fixtures; and Hot Spring Spas. We leverage our powerful brands across product categories, sales channels, and geographies to create value for our customers and shareholders. For more information about Masco Corporation, visit www.masco.com.

Safe Harbor Statement

Watkins Wellness is a subsidiary of Masco Corporation. As such, this press release contains statements that reflect views about Masco Corporation's future performance and constitute "forward–looking statements" under the Private Securities Litigation Reform Act of 1995. Forward–looking statements can be identified by words such as "outlook," "believe," "anticipate," "appear," "may," "will," "should," "intend," "plan," "estimate," "assume," "seek," "forecast," and similar references to future periods. These views about future performance involve risks and uncertainties that are difficult to predict and, accordingly, Masco Corporation's actual results may differ materially from the results discussed in these forward–looking statements. We caution you against relying on any of these forward–looking statements.

Risks and uncertainties include, among other things, the expected closing of the Sauna360 transaction and the expected benefits and synergies of the acquisition, including the expected impact on future financial and operating results and post–acquisition plans and intentions. Masco Corporation's future performance may also be affected by the levels of residential repair and remodel activity, and to a lesser extent, new home construction, the ability to maintain strong brands and to develop innovative products, the ability to maintain its public reputation, the ability to maintain its competitive position in its industries, reliance on key customers, the cost and availability of materials, dependence on suppliers and service providers, extreme weather events and changes in climate, risks associated with international operations and global strategies, the ability to achieve the anticipated benefits of its strategic initiatives, the ability to successfully execute its acquisition strategy and integrate businesses that it has acquired and may in the future acquire, the ability to attract, develop and retain a talented and diverse workforce, risks associated with cybersecurity vulnerabilities, threats and attacks, risks associated with reliance on information systems and technology and the impact of the ongoing COVID–19 pandemic on its business and operations. These and other factors are discussed in detail in Item 1A. “Risk Factors” in Masco Corporation's most recent Annual Report on Form 10–K, as well as in Masco Corporation's Quarterly Reports on Form 10–Q and in other filings it makes with the Securities and Exchange Commission. The forward–looking statement in this press release speaks only as of the date of this press release. Factors or events that could cause Masco Corporation's actual results to differ may emerge from time to time, and it is not possible to predict all of them. Unless required by law, Masco Corporation undertakes no obligation to update publicly any forward–looking statements as a result of new information, future events or otherwise.

# # #

Attachment


GLOBENEWSWIRE (Distribution ID 8883225)

TELUS Ventures Appoints Ravit Warsha Dor as Partner and Investment Director, Expanding Global Presence to Israel

TEL–AVIV, Israel and VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) — TELUS Ventures, the strategic investment arm of global communications technology company TELUS, is pleased to announce the appointment of Ravit Warsha Dor as Partner and Investment Director, leading investments out of Israel. This appointment highlights TELUS Ventures' commitment to expanding its global presence and tapping into the vibrant startup and venture capital ecosystem in Israel, unlocking new strategic investment opportunities. Since 2020, TELUS Ventures has invested over USD $25 million in Israeli–based local startups and VC funds including Zebra Medical (now Nanox), Techsee and LionBird VC.

Ravit brings over 20 years of experience in investment management, business development, product, innovation and entrepreneurship. She will play a pivotal role in uncovering innovative companies and leading investments in Israel that align with TELUS Ventures' mission of transforming and elevating companies that address society's greatest opportunities and challenges across Digital Health, Ag Tech, Smart Cities, IoT, and consumer connectivity sectors. Prior to joining TELUS, Ravit was a Partner and head of Israel at Kamet Ventures. She has also served as Head of Innovation, National Digital Health at the Israel Ministry of Health. Ravit began her career in the Israeli Army Intelligence 8200 Unit and holds degrees from Tel–Aviv University (B.Sc. Bioinformatics) and Cambridge University, UK (MBA).

“By investing in some of the most exciting Israeli–based startups, TELUS Ventures aims to foster growth and innovation in the country,” said Terry Doyle, Managing Partner and Vice–president of TELUS Ventures. “We are thrilled to welcome Ravit to the TELUS Ventures team. Her extensive experience and deep understanding of the Israeli startup landscape will be instrumental in identifying and leading strategic investment opportunities for TELUS Ventures."

"I'm proud to be joining TELUS Ventures to help drive growth and impact within Israel's dynamic startup ecosystem," added Ravit. "I see the scale of innovation coming out of Israel firsthand, I'm honored to build upon the special connection with LionBird, and I look forward to working with TELUS to empower our portfolio companies to thrive and make a lasting impact in their respective industries."

About TELUS Ventures

As the strategic investment arm of TELUS Corporation (TSX: T, NYSE: TU), TELUS Ventures is one of Canada's most active corporate venture capital funds. Operating across 30 countries globally, TELUS is a dynamic, world–leading communications technology company that designs, builds and delivers next–generation solutions for global brands across high–growth industry verticals. TELUS Ventures invests globally in companies from Seed to Pre–IPO with a focus on innovative technologies such as AgTech, Digital HealthTech, Consumer Connectivity, IoT, 5G, and Business Enablement Platforms to actively drive new solutions across the TELUS ecosystem. Led by a team of experienced operators, investors and executives, the Ventures team is passionate about creating positive social impact through financial tools and has invested in more than 100 companies since inception. For more information please visit https://www.telus.com/en/ventures.

For more information, please contact:

Franois Marchand
TELUS Public Relations
francois.marchand@telus.com


GLOBENEWSWIRE (Distribution ID 8866584)

CORRECTION: Boyden Appoints Distinguished Talent Solutions Leader Chad Hesters President & CEO

New York, Feb. 01, 2023 (GLOBE NEWSWIRE) — Correction: The original hyperline for “Chad Hesters” was incorrect. This has been rectified.

Boyden, a premier leadership and talent advisory firm with more than 70 offices in over 45 countries, is delighted to announce the appointment of Chad Hesters as President & CEO, effective immediately. He takes the reins from Trina Gordon, who retires after 12 years as CEO, 3 years as Chair, and 30+ years as a Managing Partner in the firm.

"I am honored to be appointed President & CEO of Boyden," commented Chad Hesters. "I have long admired Trina Gordon for her leadership and her custodianship of one of the oldest, global heritage brands in our industry. Boyden has a unique, collaborative culture that puts clients at the heart of their business. This collegial community is distinctive and aligns well with my style of engagement in the market. Through a shared vision and strong values, I look forward to enabling excellence for clients and nurturing the firm's current and aspiring partners".

Chad Hesters was previously a Managing Partner at Korn Ferry, where he held geographic and business line leadership roles in addition to being a Senior Client Partner in the global industrial practice. He has over 15 years of experience in executive search and organizational consulting, leveraging his global perspectives and expertise to deliver leadership consulting solutions for clients. Prior to executive search, Mr. Hesters held corporate finance roles at Hunt Oil and Shell following his early career as an Intelligence Officer with the US Navy. He holds a bachelor's degree from Texas A&M University and an MBA from the University of Colorado.

Craig Stevens, Boyden Chair, added, "Our global search for a leader to succeed our highly successful retiring CEO, Trina Gordon, has led us to another global executive, Chad Hesters. He has worked in over 20 countries and brings a comprehensive track record leading a complex leadership advisory business. His hallmark is a keen understanding of strategy while remaining close to clients and their evolving needs.

He continues, "I would like to pay tribute to Trina Gordon for her inspirational, values–driven leadership. As the first female CEO of a global executive search firm, Trina blazed the way for women leaders in our industry. While other professional services firms have taken a top–down corporate approach to strategy, Trina has remained committed to a governing structure of a true partnership, keeping the consultants who serve our clients at the center of our approach to the market. Trina established Boyden's leadership consulting Centre of Excellence, deepened our sector expertise and delivered innovations to all three lines of business. The board of directors thanks her for her exceptional performance and unwavering dedication to the partnership."

About Boyden

Boyden is a premier leadership and talent advisory firm with more than 70 offices in over 45 countries. Our global reach enables us to serve client needs anywhere they conduct business. We connect great companies with great leaders through executive search, interim management and leadership consulting solutions. Boyden is ranked amongst the top companies on Forbes' Americas Best Executive Recruiting Firms for 2021. For further information, visit www.boyden.com.

Attachment


GLOBENEWSWIRE (Distribution ID 8741106)